Dipeptidyl peptidase‐4 inhibitors and pancreatitis risk: a meta‐analysis of randomized clinical trials

@article{Monami2014DipeptidylPI,
  title={Dipeptidyl peptidase‐4 inhibitors and pancreatitis risk: a meta‐analysis of randomized clinical trials},
  author={Matteo Monami and Ilaria Dicembrini and Edoardo Mannucci},
  journal={Diabetes},
  year={2014},
  volume={16}
}
Some observational studies reporting an increased risk of pancreatitis in association with Dipeptidyl Peptidase‐4 inhibitors (DPP4i) have raised concerns on the overall safety of this class. Aim of the present meta‐analysis is the systematic collection of information on pancreatitis in randomized clinical trials with DPP4i. 
Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
TLDR
The results of this meta-analysis suggest that patients with type 2 diabetes treated with DPP4i do not have a higher risk of developing cancers than patients treated with a placebo or other drugs.
No pancreatic safety concern following glucagon‐like peptide‐1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials
TLDR
The objective of the study was to investigate this issue by pooling data on the incidence of acute pancreatitis and pancreatic cancer from four large‐scale cardiovascular outcome trials of glucagon‐like peptide‐1 receptor agonists.
Incretin‐based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
To perform a meta‐analysis of randomized controlled trials (RCTs), including 6 recently published large‐scale cardiovascular outcome trials (CVOTs), to evaluate the risk of pancreatic cancer with
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
  • A. Scheen
  • Medicine
    Expert opinion on drug safety
  • 2015
TLDR
The good tolerance/safety profile of DPP-4 inhibitors has been largely confirmed, including in more fragile populations (elderly, renal impairment) with almost no increased risk of infection or gastrointestinal AEs, no weight gain and a minimal risk of hypoglycemia.
Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials
TLDR
A meta-analysis revealed a significant association between pancreatitis and DPP-4 inhibitors; however, no such association was observed for GLP-1RAs.
Sitagliptin-Associated Pancreatitis: A Report of 4 Cases
Objective: Sitagliptin is a new oral glucose-loweri ng medication that acts via the incretin hormone system. The most common side-effects are headache and pharyngitis. Acute pancreatitis are rarely
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan
TLDR
Female and elderly DPP-4 inhibitor users had significantly elevated risks of acute pancreatitis development and further well-conducted studies are needed to confirm the findings.
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
TLDR
The physiologic function of DPP4 is revisited and its role in cardiometabolic disease is discussed based on recent experimental and clinical studies.
Effect of DPP-4 Inhibitors on the Cardiovascular System, Cancer and Pancreatitis
TLDR
The forthcoming long-term clinical studies on cardiovascular safety will provide more conclusive answers relating to the safety of DPP-4 inhibitors, including their effects on cancer and pancreatitis.
The safety of gliptins : updated data in 2018
  • A. Scheen
  • Medicine
    Expert opinion on drug safety
  • 2018
TLDR
The good tolerance/safety profile of DPP-4is has been largely confirmed, including in more fragile populations, with no gastrointestinal adverse effects and a minimal risk of hypoglycemia.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 99 REFERENCES
Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
Aim:  To evaluate the efficacy and safety of alogliptin, a potent and highly selective dipeptidyl peptidase‐4 (DPP‐4) inhibitor, in combination with glyburide in patients with type 2 diabetes
Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12‐week, double‐blind, randomized, placebo‐controlled, multicentre trial
Aim: To determine efficacy and tolerability of dutogliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, in patients with type 2 diabetes mellitus.
Efficacy and safety of adding the dipeptidyl peptidase‐4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double‐blind, placebo‐controlled study
Aims:  To evaluate the efficacy and safety of alogliptin, a new dipeptidyl peptidase‐4 inhibitor, for 26 weeks at once‐daily doses of 12.5 and 25 mg in combination with metformin in patients whose
Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
TLDR
To assess the efficacy and safety of a 24‐week treatment with sitagliptin, a highly selective once‐daily oral dipeptidyl peptidase‐4 (DPP‐4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control while on glimepiride alone or in combination with metformin.
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
TLDR
Preclinical and clinical trial data with sitagliptin to date do not indicate an increased risk of pancreatitis in patients with type 2 diabetes treated with sitgliptin, the first DPP‐4 inhibitor approved for use in patientswith T2DM.
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial
  • C. Pan, W. Yang, J. Foley
  • Medicine, Biology
    Diabetic medicine : a journal of the British Diabetic Association
  • 2008
Aims  To compare the efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor, vildagliptin, with the alpha glucosidase inhibitor, acarbose, in drug‐naive patients with Type 2 diabetes.
Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
Aim: To assess the safety and efficacy of the potent and selective dipeptidyl peptidase‐4 inhibitor linagliptin 5 mg when given for 24 weeks to patients with type 2 diabetes who were either
One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
Assess long‐term safety and efficacy of the dipeptidlyl peptidase-4 (DPP‐4) inhibitor vildagliptin in 369 patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment (RI).
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double‐blind trial
TLDR
To compare the efficacy and safety of sitagliptin and voglibose monotherapy in Japanese patients with type 2 diabetes who have inadequate glycaemic control on diet and exercise.
...
1
2
3
4
5
...